Search
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalIt is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome
AstraZeneca COVID-19 Vaccine
go.drugbank.com/drugs/DB15656ApprovedInvestigationalclots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood
Fluorescein
go.drugbank.com/drugs/DB00693ApprovedInvestigationalIt has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)
Synonyms: D&C Yellow No. 7, D and C Yellow No. 7Amphotericin B
go.drugbank.com/drugs/DB00681ApprovedInvestigationalconcentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. … Amphotericin B shows a high order of in vitro activity against many species of fungi.
Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigational[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow … It is currently marketed under the trademark TEMODAR® by Merck.[L32033]
Eucalyptus oil
go.drugbank.com/drugs/DB11114ApprovedEucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus.
Mixtures: Zam-Buk Ointment, No Touch Chest RubTemoporfin
go.drugbank.com/drugs/DB11630ApprovedIt was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
Enmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigational[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL. … [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.